

NATIONAL QUALITY FORUM

Measure Evaluation 4.1 December 2009

This form contains the measure information submitted by stewards. Blank fields indicate no information was provided. Attachments also may have been submitted and are provided to reviewers. The subcriteria and most of the footnotes from the [evaluation criteria](#) are provided in Word comments within the form and will appear if your cursor is over the highlighted area. Hyperlinks to the evaluation criteria and ratings are provided in each section.

TAP/Workgroup (if utilized): Complete all **yellow highlighted** areas of the form. Evaluate the extent to which each subcriterion is met. Based on your evaluation, summarize the strengths and weaknesses in each section.

Note: If there is no TAP or workgroup, the SC also evaluates the subcriteria (**yellow highlighted areas**).

Steering Committee: Complete all **pink** highlighted areas of the form. Review the workgroup/TAP assessment of the subcriteria, noting any areas of disagreement; then evaluate the extent to which each major criterion is met; and finally, indicate your recommendation for the endorsement. Provide the rationale for your ratings.

Evaluation ratings of the extent to which the criteria are met

C = Completely (unquestionably demonstrated to meet the criterion)

P = Partially (demonstrated to partially meet the criterion)

M = Minimally (addressed BUT demonstrated to only minimally meet the criterion)

N = Not at all (NOT addressed; OR incorrectly addressed; OR demonstrated to NOT meet the criterion)

NA = Not applicable (only an option for a few subcriteria as indicated)

(for NQF staff use) NQF Review #: 0136	NQF Project: Cardiovascular Project 2010-2013
MEASURE DESCRIPTIVE INFORMATION	
De.1 Measure Title: Heart Failure (HF): Detailed discharge instructions	
De.2 Brief description of measure: Percentage of heart failure patients discharged home with written instructions or educational material given to patient or caregiver at discharge or during the hospital stay addressing all of the following: activity level, diet, discharge medications, follow-up appointment, weight monitoring, and what to do if symptoms worsen.	
1.1-2 Type of Measure: Process	
De.3 If included in a composite or paired with another measure, please identify composite or paired measure N/A	
De.4 National Priority Partners Priority Area: Patient and family engagement	
De.5 IOM Quality Domain: Patient-centered	
De.6 Consumer Care Need: Staying healthy	

CONDITIONS FOR CONSIDERATION BY NQF	
Four conditions must be met before proposed measures may be considered and evaluated for suitability as voluntary consensus standards:	NQF Staff
A. The measure is in the public domain or an intellectual property (measure steward agreement) is signed. <i>Public domain only applies to governmental organizations. All non-government organizations must sign a measure steward agreement even if measures are made publicly and freely available.</i> A.1 Do you attest that the measure steward holds intellectual property rights to the measure and the right to use aspects of the measure owned by another entity (e.g., risk model, code set)? Yes A.2 Indicate if Proprietary Measure (as defined in measure steward agreement): A.3 Measure Steward Agreement: Government entity and in the public domain - no agreement necessary A.4 Measure Steward Agreement attached:	A Y ☒ N ☒

B. The measure owner/steward verifies there is an identified responsible entity and process to maintain and update the measure on a schedule that is commensurate with the rate of clinical innovation, but at least every 3 years. Yes, information provided in contact section	B Y● N●
C. The intended use of the measure includes <u>both</u> public reporting <u>and</u> quality improvement. ► Actual/Planned Use: Payment Program	C Y● N●
D. The requested measure submission information is complete. Generally, measures should be fully developed and tested so that all the evaluation criteria have been addressed and information needed to evaluate the measure is provided. Measures that have not been tested are only potentially eligible for a time-limited endorsement and in that case, measure owners must verify that testing will be completed within 12 months of endorsement. D.1 Testing: Yes, fully developed and tested D.2 Have NQF-endorsed measures been reviewed to identify if there are similar or related measures? Yes	D Y● N●
(for NQF staff use) Have all conditions for consideration been met? Staff Notes to Steward (if submission returned):	Met Y● N●
Staff Notes to Reviewers (issues or questions regarding any criteria):	
Staff Reviewer Name(s):	

Comment [KP]: 1a. The measure focus addresses:

- a specific national health goal/priority identified by NQF's National Priorities Partners; OR
- healthcare (e.g., affects large numbers, leading cause of morbidity/mortality, high resource use (current and/or future), severity of illness, and patient/societal consequences of poor quality).

TAP/Workgroup Reviewer Name:	
Steering Committee Reviewer Name:	
1. IMPORTANCE TO MEASURE AND REPORT	
Extent to which the specific measure focus is important to making significant gains in health care quality (safety, timeliness, effectiveness, efficiency, equity, patient-centeredness) and improving health outcomes for a specific high impact aspect of healthcare where there is variation in or overall poor performance. <i>Measures must be judged to be important to measure and report in order to be evaluated against the remaining criteria. (evaluation criteria)</i> 1a. High Impact	Eval Rating
(for NQF staff use) Specific NPP goal:	
1a.1 Demonstrated High Impact Aspect of Healthcare: Affects large numbers, Leading cause of morbidity/mortality, Severity of illness, Patient/societal consequences of poor quality 1a.2 1a.3 Summary of Evidence of High Impact: Heart failure (HF) is a major and growing public health problem in the United States that currently affects approximately 5.7 million Americans. More than 670,000 persons in the US are diagnosed with HF annually, and a person aged 40 years or older has a 1 in 5 chance of developing HF in their lifetime. HF is primarily a disease of the elderly, affecting more than 1 in 100 persons older than 65 years. HF is noted as the underlying cause of almost 59,000 deaths in the US annually, and the 5-year case fatality rate approaches 50%. HF was also responsible for more than 1 million hospitalizations and nearly 3.4 million ambulatory care visits in the US in 2006. Hospital discharges for HF increased by 126% between 1996 and 2006. It is the leading cause of hospitalization in persons older than 65 years. The estimated direct and indirect costs of HF in the United States for 2009, including inpatient and outpatient costs, were \$37.2 billion. 1a.4 Citations for Evidence of High Impact: · Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, Ferguson TB, Ford E, Furie K, Gillespie C, Go A, Greenlund K, Haase N, Hailpern S, Ho PM, Howard V, Kissela B, Kittner S, Lackland D, Lisabeth L, Marelli A, McDermott MM, Meigs J, Mozaffarian D, Mussolino M, Nichol G, Roger VL, Rosamond W, Sacco R, Sorlie P, Stafford R, Thom T, Wasserthiel-Smoller S, Wong ND, Wylie-Rosett J; on behalf of the American Heart Association Statistics Committee and Stroke	1a C● P● M● N●

Statistics Subcommittee. Heart disease and stroke statistics—2010 update: a report from the American Heart Association. Circulation. 2010;121:e46-e215.	
1b. Opportunity for Improvement 1b.1 Benefits (improvements in quality) envisioned by use of this measure: It is important to seize the opportunity that each hospitalization to educate patients with chronic conditions like HF. Giving the patient written discharge instructions helps to reinforce with the patient a wide range of issues, including medications, diet, activity level, and symptoms. It also gives patients the chance to ask important questions. Providing patients with discharge instructions reduces readmissions. Elderly people with heart failure have the highest rehospitalization rate of all adult patient groups, with estimated annual total direct healthcare expenditures exceeding \$24.3 billion. Between 29 to 47 percent of elderly HF patients are readmitted for their condition within three to six months of an initial hospitalization. Hospital performance rates have gradually increased over the years this measure has been reported to the public but significant opportunities for improvement remain (national average 88.5%). Providers understand the importance of discharge instructions for their HF patients. Ongoing use of this measure will help ensure that high performing providers maintain high performance and the many relatively lower performing providers have an impetus to improve. 1b.2 Summary of (data demonstrating performance gap) (variation or overall poor performance) across providers: National performance rates: 2Q09: 85.6% 3Q09: 86.9% 4Q09: 87.7% 1Q10: 88.5% 1b.3 Citations for data on performance gap: Clinical warehouse data: 2Q09: 161,581 HF patients, 4,019 hospitals 3Q09: 145,645 HF patients, 4,000 hospitals 4Q09: 160,288 HF patients, 4,047 hospitals 1Q10: 170,505 HF patients, 4,040 hospitals 1b.4 Summary of Data on disparities by population group: At the univariate analysis level (unadjusted odds ratios) and consistent with findings in our other HF measures, one racial/ethnic group, namely Native American, had a lower rate in this measure (76.3%) compared to the other racial/ethnic groups (Caucasian 86.3%, African-American 86.3%, Hispanic 86.6%, and Asian/Pacific Islander 87.0%). 1b.5 Citations for data on Disparities: 2009 Clinical warehouse data (Total 624,579 patients with race not missing): 414,742 Caucasian patients, 143,689 African-American patients, 51,690 Hispanic patients, 11,375 Asian/Pacific Islander patients, and 3,083 Native American patients.	1b CO PO MO NO
1c. Outcome or Evidence to Support Measure Focus 1c.1 Relationship to Outcomes (For non-outcome measures, briefly describe the relationship to desired outcome. For outcomes, describe why it is relevant to the target population): Education of heart failure patients and their families is critical. Failure of these patients to comply with physician's instructions, particularly with diet and medications, can cause exacerbation of HF. An important cause of patient's failure to comply is lack of understanding. It is, therefore, incumbent on health care professionals to be certain that patients and their families have an understanding of the causes of heart failure, prognosis, therapy, dietary restrictions, activity, importance of compliance, and the signs and symptoms of recurrent heart failure. Providing patients with discharge instructions reduces readmissions and thorough discharge planning is associated with improved patient outcomes. National guidelines strongly support the role of patient education.	1c CO PO MO NO

Comment [KP]: 1b. Demonstration of quality problems and opportunity for improvement, i.e., data demonstrating considerable variation, or overall poor performance, in the quality of care across providers and/or population groups (disparities in care).

Comment [k]: 1 Examples of data on opportunity for improvement include, but are not limited to: prior studies, epidemiologic data, measure data from pilot testing or implementation. If data are not available, the measure focus is systematically assessed (e.g., expert panel rating) and judged to be a quality problem.

Comment [k]: 1c. The measure focus is:

- an outcome (e.g., morbidity, mortality, function, health-related quality of life) that is relevant to, or associated with, a national health goal/priority, the condition, population, and/or care being addressed;

OR

- if an intermediate outcome, process, structure, etc., there is evidence that supports the specific measure focus as follows:
 - Intermediate outcome - evidence that the measured intermediate outcome (e.g., blood pressure,

Comment [k]: 4 Clinical care processes typically include multiple steps: assess → identify problem/potential problem → choose/plan intervention (with patient input) → provide intervention → evaluate impact on health status. If the measure focus is one step in such a multi-step process, the step with the greatest effect on the desired outcome should be selected as the focus of measurement. For example, although assessment of immunization status and recommending immunization are necessary steps, they are not sufficient to achieve the desired impact on health status - patients must

1c.2-3. Type of Evidence: Cohort study, Observational study, Expert opinion, Systematic synthesis of research, Meta-analysis

1c.4 Summary of Evidence (as described in the criteria; for outcomes, summarize any evidence that healthcare services/care processes influence the outcome):

Written discharge instructions or educational material given to patient and/or caregiver at hospital discharge to home or during the hospital stay which addresses activity level, diet, discharge medications, follow-up appointment, weight monitoring, and what to do if heart failure symptoms worsen are important for care coordination and transition after discharge. Education of HF patients and their families is critical and often complex. Failure of these patients to understand how best to comply with physician's instructions is often a cause of HF exacerbation leading to subsequent hospital readmission. A retrospective study of HF patients found a correlation between documentation of compliance with the aforementioned discharge instructions and reduced readmission rates.

In terms of diet instruction, excessive dietary sodium intake is a common proximate cause of worsening symptoms and hospitalization for HF exacerbation. It is not enough to simply ask patients to follow a low salt diet. Patients need to be appropriately educated about daily sodium intake targets and how to reach targets, calorie and carbohydrate restriction, etc.

In relation to follow-up instructions, several studies have examined the effect of providing more intensive delivery of discharge instructions coupled tightly with subsequent well-coordinated follow-up care for patients hospitalized with HF, many with positive results. A meta-analysis of 18 studies representing data from 8 countries randomized 3,304 older inpatients with HF to comprehensive discharge planning plus post-discharge support or usual care. During a mean observation period of 8 months, fewer intervention patients were readmitted compared with controls. Analysis of studies reporting secondary outcomes found a trend toward lower all-cause mortality, length of stay, hospital costs, and improvement in quality-of-life scores for patients assigned to an intervention compared with usual care.

1c.5 Rating of (strength/quality of evidence) (also provide narrative description of the rating and by whom):

[ACCF/AHA]: Level of Evidence C (Consensus opinion of experts, case studies, or standard of care; Very limited populations evaluated). [HFSA]: Strength of Evidence B (Cohort and Case-Control Studies; Post hoc, subgroup analysis, and meta-analysis; Prospective observational studies or registries); Strength of Evidence C (Expert Opinion, Observational studies-epidemiologic findings, Safety Reporting from large-scale use in practice)

1c.6 Method for rating evidence: [ACCF/AHA]

The methodology used by the ACCF/AHA Task Force on Practice Guidelines is fully documented in their publication "Methodology Manual and Policies From the ACCF/AHA Task Force on Practice Guidelines" (http://assets.cardiosource.com/Methodology_Manual_for_ACC_AHA_Writing_Committees.pdf). The guidelines are based upon a comprehensive assessment, both electronic and manual, of the English-language medical literature. This search focuses on high-quality randomized controlled trials, meta-analyses and systematic reviews, and when applicable observational studies. In some cases where higher quality data is not available, observational studies and case series are also considered. The quality of the design and execution of these studies is determined. When appropriate, data tables are generated from the available literature. After a review of the available literature, the writing committee rates the evidence according to the schemes outlined in their publication.

[HFSA]

Strength of Evidence A - Randomized, Controlled, Clinical Trials; May be assigned based on results of a single trial: Randomized controlled clinical trials provide what is considered the most valid form of guideline evidence. Some guidelines require at least 2 positive randomized clinical trials before the evidence for a recommendation can be designated level A. The HFSA guideline committee has occasionally accepted a single randomized, controlled, outcome-based clinical trial as sufficient for level A evidence when the single trial is large with a substantial number of endpoints and has consistent and robust outcomes. However, randomized clinical trial data, whether derived from one or multiple trials, have not been taken simply at face value. They have been evaluated for: (1) endpoints studied, (2) level of significance, (3) reproducibility of findings, (4) generalizability of study results, and (5) sample size and

Comment [k]: 3 The strength of the body of evidence for the specific measure focus should be systematically assessed and rated (e.g., USPSTF grading system <http://www.ahrq.gov/clinic/uspstf07/methods/benefit.htm>). If the USPSTF grading system was not used, the grading system is explained including how it relates to the USPSTF grades or why it does not. However, evidence is not limited to quantitative studies and the best type of evidence depends upon the question being studied (e.g., randomized controlled trials appropriate for studying drug efficacy are not well suited for complex system changes). When qualitative studies are used, appropriate qualitative research criteria are used to judge the strength of the evidence.

number of events on which outcome results are based.

- Strength of Evidence B - Cohort and Case-Control Studies; Post hoc, subgroup analysis, and meta-analysis; Prospective observational studies or registries: The HFSA guideline process also considers evidence arising from cohort studies or smaller clinical trials with physiologic or surrogate endpoints. This level B evidence is derived from studies that are diverse in design and may be prospective or retrospective in nature. They may involve subgroup analyses of clinical trials or have a case control or propensity design using a matched subset of trial populations. Dose-response studies, when available, may involve all or a portion of the clinical trial population. Evidence generated from these studies has well-recognized, inherent limitations. Nevertheless, their value is enhanced through attention to factors such as pre-specification of hypotheses, biologic rationale, and consistency of findings between studies and across different populations.

- Strength of Evidence C - Expert Opinion; Observational studies-epidemiologic findings; Safety Reporting from large-scale use in practice: The present HFSA guideline makes extensive use of expert opinion, or C-level evidence. The need to formulate recommendations based on level C evidence is driven primarily by a paucity of scientific evidence in many areas critical to a comprehensive guideline. For example, the diagnostic process and the steps used to evaluate and monitor patients with established HF have not been the subject of clinical studies that formally test the validity of one approach versus another. In areas such as these, recommendations must be based on expert opinion or go unaddressed.

1c.7 Summary of Controversy/Contradictory Evidence: There are no randomized trials that prove the efficacy of discharge instructions. [Patterson ME, Hernandez AF, Hammill BG, Fonarow GC, Peterson ED, Schulman KA, Curtis LH. Process of care performance measures and long-term outcomes in patients hospitalized with heart failure. *Med Care*. 2010 Mar;48(3):210-6.]

1c.8 Citations for Evidence (other than guidelines): • VanSuch M, Naessens JM, Stroebe RJ, Huddleston JM, Williams AR. Effect of discharge instructions on readmission of hospitalised patients with heart failure: do all of the Joint Commission on Accreditation of Healthcare Organizations heart failure core measures reflect better care? *Qual Saf Health Care*. 2006 Dec;15(6):414-7.

- Bennet SJ, Huster GA, Baker SL, Milgrom ALB, Kirchgassner Birt J, et al. Characterization of the precipitants of hospitalization for heart failure decompensation. *Am J Crit Care* 1998;7:168e74.

- Michalsen A, König G, Thimme W. Preventable causative factors leading to hospital admission with decompensated heart failure. *Heart* 1998;80:437e41.

- Tsuyuki RT, McKelvie RS, Arnold JM, Avezum A Jr, Barretto AC, Carvalho AC, et al. Acute precipitants of congestive heart failure exacerbations. *Arch Intern Med* 2001;161:2337e42.

- McAlister FA, Stewart S, Ferrua S, et al. Multidisciplinary strategies for the management of heart failure patients at high risk for admission: a systematic review of randomized trials. *J Am Coll Cardiol*. 2004;44:810 -9.

- Naylor MD, Broton DA, Campbell RL, et al. Transitional care of older adults hospitalized with heart failure: a randomized, controlled trial. *J Am Geriatr Soc*. 2004;52:675- 84.

- Casey DE Jr., Abraham WT, Guo L, et al. Reducing heart failure hospitalizations and readmissions with heart failure advocates: A call to action for nursing. *Circulation*. 2007;115:e559-60.

- Windham BG, Bennett RG, Gottlieb S. Care management interventions for older patients with congestive heart failure. *Am J Manag Care*. 2003;9:447-59.

- Phillips CO, Wright SM, Kern DE, et al. Comprehensive discharge planning with postdischarge support for older patients with congestive heart failure: a meta-analysis. *JAMA*. 2004;291:1358-67.

1c.9 Quote the Specific guideline recommendation (including guideline number and/or page number): [ACCF/AHA]

17. Comprehensive written discharge instructions for all patients with a hospitalization for HF and their caregivers is strongly recommended, with special emphasis on the following 6 aspects of care: diet, discharge medications, with a special focus on adherence, persistence, and up-titration to recommended doses of ACE inhibitor/ARB and beta-blocker medication, activity level, follow-up appointments, daily weight monitoring, and what to do if HF symptoms worsen. [p. 1363]

[HFSA]

6.1 Dietary instruction regarding sodium intake is recommended in all patients with HF. Patients with HF and diabetes, dyslipidemia, or severe obesity should be given specific dietary instructions. [p. 485]

12.25 It is recommended that criteria be met before a patient with HF is discharged from the hospital ..

Patient and family education completed, including clear discharge instructions. [p. 500]
 12.26 Discharge planning is recommended as part of the management of patients with ADHF. Discharge planning should address the following issues: Details regarding medication, dietary sodium restriction, and recommended activity level ... Follow-up by phone or clinic visit early after discharge to reassess volume status .. Medication and dietary compliance ... Monitoring of body weight, electrolytes and renal function. [p. 500]

1c.10 Clinical Practice Guideline Citation: - Lindenfeld J, Albert NM, Boehmer JP, Collins SP, Ezekowitz JA, Givertz MM, Klapholz M, Moser DK, Rogers JG, Starling RC, Stevenson WG, Tang WHW, Teerlink JR, Walsh MN. Executive Summary: HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Card Fail 2010;16:475e539.

- Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, Ganiats TG, et al, writing on behalf of the 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult Writing Committee. 2009 focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2009;53:1343-82.

1c.11 National Guideline Clearinghouse or other URL:
<http://www.sccp.org/dnn/WebDocs/HFSA%202010%20HF%20Guidelines.pdf>,
<http://content.onlinejacc.org/cgi/reprint/53/15/1343.pdf>

1c.12 Rating of strength of recommendation (also provide narrative description of the rating and by whom):

[ACCF/AHA] - Class I recommendation - Conditions for which there is evidence and/or general agreement that a given procedure or treatment is useful and effective. Benefit >>> Risk. Procedure/treatment should be performed/administered. [HFSA] - Strength of recommendation - "Is recommended": The recommended therapy or management process should be followed as often as possible in individual patients (part of routine care).

1c.13 Method for rating strength of recommendation (If different from USPSTF system, also describe rating and how it relates to USPSTF):

[ACCF/AHA] The methodology used by the ACCF/AHA Task Force on Practice Guidelines is fully documented in their publication "Methodology Manual and Policies From the ACCF/AHA Task Force on Practice Guidelines" (http://assets.cardiosource.com/Methodology_Manual_for_ACC_AHA_Writing_Committees.pdf). Recommendations are assigned strength by the Task Force based upon evidence, benefit vs. risk vs. harm, and patient preference.

[HFSA]

There are several degrees of favorable recommendations and a single category for therapies felt to be not effective.

- "Is recommended": The recommended therapy or management process should be followed as often as possible in individual patients (part of routine care). Exceptions are carefully delineated and should be minimized.

- "Should be considered": A majority of patients should receive the intervention, with some discretion involving individual patients.

- "May be considered": Individualization of therapy is indicated.

- "Is not recommended": Therapeutic intervention should not be used.

Both the ACCF/AHA Guidelines and the USPSTF assess evidence with respect to two parameters: 1) the magnitude of the benefit, and 2) the certainty of this benefit. However, they use different coding systems. In ascertaining magnitude of the benefit, the ACCF/AHA uses a Class I-III scale and the USPSTF uses a high-moderate-low scale. In determining the certainty of this benefit, the ACCF/AHA uses levels of evidence A-C and USPSTF uses a high-moderate-low scale. The HFSA guidelines also characterize their recommendations according to both the weight of evidence (on an A, B, C scale) as well as the strength of the recommendation (categorized as "is recommended," "should be considered," "may be considered," and "is not recommended").

1c.14 Rationale for using this guideline over others:

The ACCF/AHA and HFSA guidelines are the only national guidelines that address the therapy of patients with HF; they use an explicit and transparent methodology; and have thus served as the foundation of

Comment [k]: USPSTF grading system <http://www.ahrq.gov/clinic/uspstf/grade.htm>: A - The USPSTF recommends the service. There is high certainty that the net benefit is substantial. B - The USPSTF recommends the service. There is high certainty that the net benefit is moderate or there is moderate certainty that the net benefit is moderate to substantial. C - The USPSTF recommends against routinely providing the service. There may be considerations that support providing the service in an individual patient. There is at least moderate certainty that the net benefit is small. Offer or provide this service only if other considerations support the offering or providing the service in an individual patient. D - The USPSTF recommends against the service. There is moderate or high certainty that the service has no net benefit or that the harms outweigh the benefits. I - The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of the service. Evidence is lacking, of poor quality, or conflicting, and the balance of benefits and harms cannot be determined.

national quality metrics.	
TAP/Workgroup: What are the strengths and weaknesses in relation to the subcriteria for <i>Importance to Measure and Report</i>?	1
Steering Committee: Was the threshold criterion, <i>Importance to Measure and Report</i>, met? Rationale:	1 Y ☒ N ☒
2. SCIENTIFIC ACCEPTABILITY OF MEASURE PROPERTIES	
Extent to which the measure, <u>as specified</u> , produces consistent (reliable) and credible (valid) results about the quality of care when implemented. (evaluation criteria)	Eval Rating
2a. MEASURE SPECIFICATIONS	
S.1 Do you have a web page where current detailed measure specifications can be obtained? S.2 If yes, provide web page URL:	2a- specs C ☒ P ☒ M ☒ N ☒
2a. Precisely Specified	
2a.1 Numerator Statement (Brief, text description of the numerator - what is being measured about the target population, e.g. target condition, event, or outcome): HF patients with documentation that they or their caregivers were given written discharge instructions or other educational material addressing all of the following: 1.activity level 2.diet 3.discharge medications 4.follow-up appointment 5.weight monitoring 6.what to do if symptoms worsen	
2a.2 Numerator Time Window (The time period in which cases are eligible for inclusion in the numerator): From hospital arrival to time of hospital discharge	
2a.3 Numerator Details (All information required to collect/calculate the numerator, including all codes, logic, and definitions): Refer to http://www.qualitynet.org/dcs/ContentServer?c=Page&pagename=QnetPublic%2FPages%2FQnetTier4&cid=1228760129036 : · Section 1 - Data Dictionary Alphabetical Data Dictionary - pages 1-121 through 1-122, 1-125 through 1-126, 1-129 through 1-130, 1-133 through 1-136, and 1-139 through 1-142. · Section 2 - Measurement Information Section 2.2 - Heart Failure (HF) - pages HF-1-1 through HF-1-7.	
2a.4 Denominator Statement (Brief, text description of the denominator - target population being measured): HF patients discharged home (ICD-9-CM principal diagnosis of HF: 402.01, 402.11, 402.91, 404.01, 404.03, 404.11, 404.13, 404.91, 404.93, 428.0, 428.1, 428.20, 428.21, 428.22, 428.23, 428.30, 428.31, 428.32, 428.33, 428.40, 428.41, 428.42, 428.43, 428.9); and a discharge to home, home care, or court/law enforcement	
2a.5 Target population gender: Female, Male	
2a.6 Target population age range: Greater than or equal to 18 years old	
2a.7 Denominator Time Window (The time period in which cases are eligible for inclusion in the denominator): From hospital arrival to time of hospital discharge	

Comment [KP]: 2a. The measure is well defined and precisely specified so that it can be implemented consistently within and across organizations and allow for comparability. The required data elements are of high quality as defined by NQF's Health Information Technology Expert Panel (HITEP).

2a.8 Denominator Details (All information required to collect/calculate the denominator - the target population being measured - including all codes, logic, and definitions):

ICD-9-CM Principal Diagnosis codes:

402.01: Hypertensive heart disease, malignant, with heart failure
 402.11: Hypertensive heart disease, benign, with heart failure
 402.91: Hypertensive heart disease, unspecified, with heart failure
 404.01: Hypertensive heart and chronic kidney disease, malignant, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified
 404.03: Hypertensive heart and chronic kidney disease, malignant, with heart failure and with chronic kidney disease stage V or end stage renal disease
 404.11: Hypertensive heart and chronic kidney disease, benign, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified
 404.13: Hypertensive heart and chronic kidney disease, benign, with heart failure and chronic kidney disease stage V or end stage renal disease
 404.91: Hypertensive heart and chronic kidney disease, unspecified, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified
 404.93: Hypertensive heart and chronic kidney disease, unspecified, with heart failure and chronic kidney disease stage V or end stage renal disease
 428.0: Congestive heart failure, unspecified
 428.1: Left heart failure
 428.20: Unspecified systolic heart failure
 428.21: Acute systolic heart failure
 428.22: Chronic systolic heart failure
 428.23: Acute on chronic systolic heart failure
 428.30: Unspecified diastolic heart failure
 428.31: Acute diastolic heart failure
 428.32: Chronic diastolic heart failure
 428.33: Acute on chronic diastolic heart failure
 428.40: Unspecified combined systolic and diastolic heart failure
 428.41: Acute combined systolic and diastolic heart failure
 428.42: Chronic combined systolic and diastolic heart failure
 428.43: Acute on chronic combined systolic and diastolic heart failure
 428.9: Heart failure, unspecified

Discharge Disposition - Refer to

<http://www.qualitynet.org/dcs/ContentServer?c=Page&pagename=QnetPublic%2FPPage%2FQnetTier4&cid=1228760129036>:

· Section 1 - Data Dictionary | Alphabetical Data Dictionary - pages 1-118 through 1-120.

2a.9 Denominator Exclusions (Brief text description of exclusions from the target population): Exclusions:

- <18 years of age
- Patients who have a length of stay greater than 120 days
- Patients enrolled in clinical trials
- Patients with comfort measures only documented
- Patients who had a left ventricular assistive device (LVAD) or heart transplant procedure during hospital stay (ICD-9-CM procedure code of LVAD and Heart Transplant: 33.6, 37.51, 37.52, 37.53, 37.54, 37.60, 37.62, 37.63, 37.65, 37.66, 37.68)

2a.10 Denominator Exclusion Details (All information required to collect exclusions to the denominator, including all codes, logic, and definitions):

Refer to

<http://www.qualitynet.org/dcs/ContentServer?c=Page&pagename=QnetPublic%2FPPage%2FQnetTier4&cid=1228760129036>:

- Section 1 - Data Dictionary | Alphabetical Data Dictionary - pages 1-20 through 1-21, 1-90, 1-98 through 1-104, 1-117 through 1-120, 1-201, and 1-204 through 1-205.
- Section 2 - Measurement Information | Section 2.2 - Heart Failure (HF) - pages HF-5 plus HF-1-1 through HF-1-7

2a.11 Stratification Details/Variables (All information required to stratify the measure including the

Comment [k]: 11 Risk factors that influence outcomes should not be specified as exclusions.
 12 Patient preference is not a clinical exception to eligibility and can be influenced by provider interventions.

<i>stratification variables, all codes, logic, and definitions):</i> N/A
2a.12-13 Risk Adjustment Type: No risk adjustment necessary
2a.14 Risk Adjustment Methodology/Variables (<i>List risk adjustment variables and describe conceptual models, statistical models, or other aspects of model or method):</i> N/A
2a.15-17 Detailed risk model available Web page URL or attachment:
2a.18-19 Type of Score: Rate/proportion 2a.20 Interpretation of Score: Better quality = Higher score 2a.21 Calculation Algorithm (<i>Describe the calculation of the measure as a flowchart or series of steps):</i> Refer to http://www.qualitynet.org/dcs/ContentServer?c=Page&pagename=QnetPublic%2FPage%2FQnetTier4&cid=1228760129036: Section 2 - Measurement Information Section 2.2 - Heart Failure (HF) - pages HF-5 plus HF-1-4 through HF-1-7.
2a.22 Describe the method for discriminating performance (<i>e.g., significance testing):</i> Benchmarks are established using the ABC methodology, based on the actual performance of the top facilities. ABC benchmarks identify superior performance and encourage poorer performers to improve. The methodology is a data-driven, peer-group performance feedback used to positively affect outcomes.
2a.23 Sampling (Survey) Methodology <i>If measure is based on a sample (or survey), provide instructions for obtaining the sample, conducting the survey and guidance on minimum sample size (response rate):</i> Patients admitted to the hospital for inpatient acute care with an ICD-9-CM Principal Diagnosis Code for HF as defined in section 2a.8, no ICD-9-CM Principal or Other Procedure Code of Left Ventricular Assistive Device (LVAD) or Heart Transplant as defined in section 2a.9, patient age greater than or equal to 18 years, and a length of stay less than or equal to 120 days would be included in the initial patient population and eligible to be sampled. Monthly Sample Size Based on Population Size (Average monthly initial patient population size: Minimum required sample size): >= 506: 102 131-505: 20% of Initial Patient Population size 26-130: 26 < 26: 100%
2a.24 Data Source (<i>Check the source(s) for which the measure is specified and tested)</i> Other, Paper medical record/flow-sheet
2a.25 Data source/data collection instrument (<i>Identify the specific data source/data collection instrument, e.g. name of database, clinical registry, collection instrument, etc.):</i> Centers for Medicare & Medicaid Services (CMS) Abstraction & Reporting Tool (CART). Vendor tools also available.
2a.26-28 Data source/data collection instrument reference web page URL or attachment: URL http://www.qualitynet.org/dcs/ContentServer?c=Page&pagename=QnetPublic%2FPage%2FQnetTier3&cid=1135267770141
2a.29-31 Data dictionary/code table web page URL or attachment: URL Refer to http://www.qualitynet.org/dcs/ContentServer?c=Page&pagename=QnetPublic%2FPage%2FQnetTier4&cid=1228760129036: Section 1 - Data Dictionary Alphabetical Data Dictionary
2a.32-35 Level of Measurement/Analysis (<i>Check the level(s) for which the measure is specified and tested)</i> Facility/Agency, Other

2a.36-37 Care Settings (Check the setting(s) for which the measure is specified and tested) Hospital	
2a.38-41 Clinical Services (Healthcare services being measured, check all that apply)	
TESTING/ANALYSIS	
2b. Reliability testing	
2b.1 Data/sample (description of data/sample and size): CDAC (Clinical Data Abstraction Center) validation sample: 3Q09.	
2b.2 Analytic Method (type of reliability) & rationale, method for testing): CDAC validation sampling involves SDPS selection of sample of 5 cases/quarter across all topics (AMI, HF, Pneumonia, etc.) from each hospital with a minimum of 6 discharges (across all topics) in the Clinical Data Warehouse within 4 months + 15 days following 3Q09. Hospital-abstracted data is compared to CDAC-adjudicated data.	
2b.3 Testing Results (reliability statistics, assessment of adequacy in the context of norms for the test conducted): Clinical Trial - 98.9% Comfort Measures Only - 94.3% Discharge Instructions Address Activity - 96.3% Discharge Instructions Address Diet - 97.1% Discharge Instructions Address Follow-up - 96.4% Discharge Instructions Address Medications - 81.7% Discharge Instructions Address Symptoms Worsening - 91.7% Discharge Instructions Address Weight Monitoring - 93.6%	2b CO PO MO NO
2c. Validity testing	
2c.1 Data/sample (description of data/sample and size): Face validity is regularly assessed with the Technical Expert Panel responsible for reviewing and supporting the measure topic.	
2c.2 Analytic Method (type of validity) & rationale, method for testing): Face validity	2c CO PO MO NO
2c.3 Testing Results (statistical results, assessment of adequacy in the context of norms for the test conducted): N/A	
2d. Exclusions Justified	
2d.1 Summary of Evidence supporting exclusion(s): The exclusions of age < 18 years, length of stay > 120 days, and enrollment in a clinical trial are common to the other measures in the HF measure set, and to the inpatient Hospital Inpatient Quality Reporting Program measure set in general. Patients with documented comfort measures only or those discharged to hospice are appropriate exclusions, as the goal in these cases is palliative care - Therefore, written discharge instructions for the patient/caregiver to help ensure patient compliance post-discharge become relatively irrelevant. Although discharge instructions are arguably important in LVAD and heart transplant cases, these cases are excluded due to the population sampling methodology that this measure must share with the other HF measures in the HF measure set. Patients who leave against medical advice or who expire are appropriately excluded, and it is sensible for those who are discharged to another hospital or other health care facility (where the patient goes on to continue treatment and responsibility of care does not yet fall on him/her) to be omitted as well. Exclusions in this measure are concordant with both the 2005 ACC/AHA Clinical Performance Measures for Adults With Chronic Heart Failure and the 2010 ACC/AHA/PCPI Heart Failure Performance Measure Set.	2d CO PO MO NO NAO

Comment [KP]: 2b. Reliability testing demonstrates the measure results are repeatable, producing the same results a high proportion of the time when assessed in the same population in the same time period.

Comment [k]: 8 Examples of reliability testing include, but are not limited to: inter-rater/abstractor or intra-rater/abstractor studies; internal consistency for multi-item scales; test-retest for survey items. Reliability testing may address the data items or final measure score.

Comment [KP]: 2c. Validity testing demonstrates that the measure reflects the quality of care provided, adequately distinguishing good and poor quality. If face validity is the only validity addressed, it is systematically assessed.

Comment [k]: 9 Examples of validity testing include, but are not limited to: determining if measure scores adequately distinguish between providers known to have good or poor quality assessed by another valid method; correlation of measure scores with another valid indicator of quality for the specific topic; ability of measure scores to predict scores on some other related valid measure; content validity for multi-item scales/tests. Face validity is a subjective assessment by experts of whether the measure reflects the quality of care (e.g., whether the proportion of patients with BP < 140/90 is a marker of quality). If face validity is the only validity addressed, it is systematically assessed (e.g., ratings by relevant stakeholders) and the measure is judged to represent quality care for the specific topic and that the measure focus is the most important aspect of quality for the specific topic.

Comment [KP]: 2d. Clinically necessary measure exclusions are identified and must be:

- supported by evidence of sufficient frequency of occurrence so that results are distorted without the exclusion;

AND

- a clinically appropriate exception (e.g., contraindication) to eligibility for the measure focus;

Comment [k]: 10 Examples of evidence that an exclusion distorts measure results include, but are not limited to: frequency of occurrence, sensitivity analyses with and without the exclusion, and variability of exclusions across providers.

2d.2 Citations for Evidence: - Bonow RO, Bennett S, Casey DE, Ganiats TG, Hlatky MA, Konstam MA, et al. ACC/AHA Clinical Performance Measures for Adults With Chronic Heart Failure: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Heart Failure Clinical Performance Measures). J Am Coll Cardiol. 2005;46:1144-78. - Bonow RO, Ganiats TG, Beam CT, Blake K, Casey DE, Goodlin SJ, et al. December 2010. American College of Cardiology Foundation/American Heart Association/Physician Consortium for Performance Improvement Heart Failure Performance Measurement Set (voting draft). In American Medical Association. Retrieved December 2010, from http://www.ama-assn.org/ama1/pub/upload/mm/370/heart-failure-measures.pdf.	
2d.3 Data/sample (description of data/sample and size): Clinical warehouse data: 245,783 HF patients, 4,117 hospitals, 1Q10.	
2d.4 Analytic Method (type analysis & rationale): A frequency count was conducted to calculate the percentages outlined in section 2d.5. Frequency counts are a simple, efficient way to determine the occurrence of specific values of a data element in a given data set.	
2d.5 Testing Results (e.g., frequency, variability, sensitivity analyses): Rates of Exclusion: - Patients with comfort measures only documented: 1.2% - Patients enrolled in clinical trials: 0.2% - Patients not discharged to home/home care or not discharged/transferred to court/law enforcement: 29.3%	
2e. Risk Adjustment for Outcomes/ Resource Use Measures	
2e.1 Data/sample (description of data/sample and size): N/A	
2e.2 Analytic Method (type of risk adjustment, analysis, & rationale): N/A	2e
2e.3 Testing Results (risk model performance metrics): N/A	CO
2e.4 If outcome or resource use measure is not risk adjusted, provide rationale: N/A	MO
2f. Identification of Meaningful Differences in Performance	NO
2f.1 Data/sample from Testing or Current Use (description of data/sample and size): Clinical warehouse data: 2Q09: 161,581 HF patients, 4,019 hospitals 3Q09: 145,645 HF patients, 4,000 hospitals 4Q09: 160,288 HF patients, 4,047 hospitals 1Q10: 170,505 HF patients, 4,040 hospitals	NAO
2f.2 Methods to identify statistically significant and practically/meaningfully differences in performance (type of analysis & rationale): Analysts review quarterly benchmarks established (using the ABC methodology) and trends to identify differences in performance scores and investigate the possible causes. ABC benchmarks identify superior performance and encourage poorer performers to improve. The methodology is a data-driven, peer-group performance feedback used to positively affect outcomes. If measure specifications (algorithms, data elements) are found to cause the difference in performance, they are reviewed for possible updates.	2f
2f.3 Provide Measure Scores from Testing or Current Use (description of scores, e.g., distribution by quartile, mean, median, SD, etc.; identification of statistically significant and meaningfully differences in	CO

Comment [KP]: 2e. For outcome measures and other measures (e.g., resource use) when indicated:

- an evidence-based risk-adjustment strategy (e.g., risk models, risk stratification) is specified and is based on patient clinical factors that influence the measured outcome (but not disparities in care) and are present at start of care;

OR
rationale/data support no risk adjustment.

Comment [k]: 13 Risk models should not obscure disparities in care for populations by including factors that are associated with differences/inequalities in care such as race, socioeconomic status, gender (e.g., poorer treatment outcomes of African American men with prostate cancer, inequalities in treatment for CVD risk factors between men and women). It is preferable to stratify measures by race and socioeconomic status rather than adjusting out differences.

Comment [KP]: 2f. Data analysis demonstrates that methods for scoring and analysis of the specified measure allow for identification of statistically significant and practically/clinically meaningful differences in performance.

Comment [k]: 14 With large enough sample sizes, small differences that are statistically significant may or may not be practically or clinically meaningful. The substantive question may be, for example, whether a statistically significant difference of one percentage point in the percentage of patients who received smoking cessation counseling (e.g., 74% v. 75%) is clinically meaningful; or whether a statistically significant difference of \$25 in cost for an episode of care (e.g., \$5,000 v. \$5,025) is practically meaningful. Measures with overall poor performance may not demonstrate much variability across providers.

performance): National performance rates: 2Q09: 85.6% (benchmark 99.7%) 3Q09: 86.9% (benchmark 99.8%) 4Q09: 87.7% (benchmark 99.8%) 1Q10: 88.5% (benchmark 99.9%)	
2g. Comparability of Multiple Data Sources/Methods	
2g.1 Data/sample (description of data/sample and size): Both paper records and electronic health records can be used to collect data. Some allowances have been made as facilities incorporate EHRs in their facilities because vendors do not utilize identical data fields, but customize products according to facility need and preferences.	
2g.2 Analytic Method (type of analysis & rationale): No tests have been performed on this measure to determine comparability of sources (paper medical record vs. EHR).	2g C● P● M● N● NA●
2g.3 Testing Results (e.g., correlation statistics, comparison of rankings): N/A	
2h. Disparities in Care	
2h.1 If measure is stratified, provide stratified results (scores by stratified categories/cohorts): Not stratified, but results according to race, sex, etc can be determined.	
2h.2 If disparities have been reported/identified, but measure is not specified to detect disparities, provide follow-up plans: Although preliminary univariate analyses suggested a possible disparity (as described in 1b.4), further analyses are needed to control for the simultaneous effect of other potential factors such as age, gender, comorbidity, and hospital characteristics and to take into account the correlation/cluster effect of patients discharged from the same hospitals.	2h C● P● M● N● NA●
TAP/Workgroup: What are the strengths and weaknesses in relation to the subcriteria for Scientific Acceptability of Measure Properties?	2
Steering Committee: Overall, to what extent was the criterion, Scientific Acceptability of Measure Properties, met? Rationale:	2 C● P● M● N●
3. USABILITY	
Extent to which intended audiences (e.g., consumers, purchasers, providers, policy makers) can understand the results of the measure and are likely to find them useful for decision making. (evaluation criteria)	Eval Rating
3a. Meaningful, Understandable, and Useful Information	
3a.1 Current Use: In use	
3a.2 Use in a public reporting initiative (disclosure of performance results to the public at large) (If used in a public reporting initiative, provide name of initiative(s), locations, Web page URL(s). If not publicly reported, state the plans to achieve public reporting within 3 years): Hospital Inpatient Quality Reporting Program: · http://www.qualitynet.org/dcs/ContentServer?c=Page&pagename=QnetPublic%2FPage%2FQnetTier2&cid=1138115987129 · http://www.hospitalcompare.hhs.gov/	3a C● P● M● N●
3a.3 If used in other programs/initiatives (If used in quality improvement or other programs/initiatives,	

Comment [KP]: 2g. If multiple data sources/methods are allowed, there is demonstration they produce comparable results.

Comment [KP]: 2h. If disparities in care have been identified, measure specifications, scoring, and analysis allow for identification of disparities through stratification of results (e.g., by race, ethnicity, socioeconomic status, gender); OR rationale/data justifies why stratification is not necessary or not feasible.

Comment [KP]: 3a. Demonstration that information produced by the measure is meaningful, understandable, and useful to the intended audience(s) for both public reporting (e.g., focus group, cognitive testing) and informing quality improvement (e.g., quality improvement initiatives). An important outcome that may not have an identified improvement strategy still can be useful for informing quality improvement by identifying the need for and stimulating new approaches to improvement.

name of initiative(s), locations, Web page URL(s). If not used for QI, state the plans to achieve use for QI within 3 years): Hospital Inpatient Quality Reporting Program (Measures can be used by individual hospitals for internal quality improvement): · http://www.qualitynet.org/dcs/ContentServer?c=Page&pagename=QnetPublic%2FPage%2FQnetTier2&cid=1138115987129 · http://www.hospitalcompare.hhs.gov/ Additionally, the Joint Commission also uses this measure for accreditation. Testing of Interpretability (Testing that demonstrates the results are understood by the potential users for public reporting and quality improvement) 3a.4 Data/sample (description of data/sample and size): Unknown. [Feedback on the Hospital Compare website (used for public reporting) is collected through another contractor.] 3a.5 Methods (e.g., focus group, survey, QI project): Voluntary electronic survey by visitors to website. 3a.6 Results (qualitative and/or quantitative results and conclusions): Not available.	
3b/3c. Relation to other NQF-endorsed measures	
3b.1 NQF # and Title of similar or related measures:	
(for NQF staff use) Notes on similar/related <u>endorsed</u> or submitted measures:	
3b. Harmonization If this measure is related to measure(s) already <u>endorsed by NQF</u> (e.g., same topic, but different target population/setting/data source or different topic but same target population): 3b.2 Are the measure specifications <u>harmonized</u>? If not, why?	3b C● P● M● N● NA●
3c. Distinctive or Additive Value 3c.1 Describe the distinctive, improved, or additive value this measure provides to existing NQF-endorsed measures: 5.1 If this measure is similar to measure(s) already endorsed by NQF (i.e., on the same topic and the same target population), Describe why it is a more valid or efficient way to measure quality: No NQF-endorsed measures with same topic and target population.	3c C● P● M● N● NA●
TAP/Workgroup: What are the strengths and weaknesses in relation to the subcriteria for Usability?	3
Steering Committee: Overall, to what extent was the criterion, Usability, met?	3
Rationale:	C● P● M● N●
4. FEASIBILITY	
Extent to which the required data are readily available, retrievable without undue burden, and can be implemented for performance measurement. (<u>evaluation criteria</u>)	<u>Eval Rating</u>
4a. Data Generated as a Byproduct of Care Processes	4a
4a.1-2 How are the data elements that are needed to compute measure scores generated?	C● P● M●
Data generated as byproduct of care processes during care delivery (Data are generated and used by	

Comment [KP]: 3b. The measure specifications are harmonized with other measures, and are applicable to multiple levels and settings.

Comment [k]: 16 Measure harmonization refers to the standardization of specifications for similar measures on the same topic (e.g., *influenza immunization* of patients in hospitals or nursing homes), or related measures for the same target population (e.g., eye exam and HbA1c for *patients with diabetes*), or definitions applicable to many measures (e.g., age designation for children) so that they are uniform or compatible, unless differences are dictated by the evidence. The dimensions of harmonization can include numerator, denominator, exclusions, and data source and collection instructions. The extent of harmonization depends on the relationship of the measures, the evidence for the specific measure focus, and differences in data sources.

Comment [KP]: 3c. Review of existing endorsed measures and measure sets demonstrates that the measure provides a distinctive or additive value to existing NQF-endorsed measures (e.g., provides a more complete picture of quality for a particular condition or aspect of healthcare, is a more valid or efficient way to measure).

Comment [KP]: 4a. For clinical measures, required data elements are routinely generated concurrent with and as a byproduct of care processes during care delivery. (e.g., BP recorded in the electronic record, not abstracted from the record later by other personnel; patient self-assessment tools, e.g., depression scale; lab values, meds, etc.)

healthcare personnel during the provision of care, e.g., blood pressure, lab value, medical condition), Coding/abstraction performed by someone other than person obtaining original information (E.g., DRG, ICD-9 codes on claims, chart abstraction for quality measure or registry)	NO
4b. Electronic Sources	
4b.1 Are all the data elements available electronically? (<i>elements that are needed to compute measure scores are in defined, computer-readable fields, e.g., electronic health record, electronic claims</i>) No	4b CO PO MO NO
4b.2 If not, specify the near-term path to achieve electronic capture by most providers. Retooling work with HHS is expected to be completed in the near future.	
4c. Exclusions	
4c.1 Do the specified exclusions require additional data sources beyond what is required for the numerator and denominator specifications? No	4c CO PO MO NO NA
4c.2 If yes, provide justification.	
4d. Susceptibility to Inaccuracies, Errors, or Unintended Consequences	
4d.1 Identify susceptibility to inaccuracies, errors, or unintended consequences of the measure and describe how these potential problems could be audited. If audited, provide results. 1. It is important to note that this measure focuses on whether activity, diet, etc. after discharge were addressed in the written instructions sent home with the patient. It does not measure the quality of those instructions (e.g., accuracy of instructions, clarity, customized to patient needs). In some cases, quality of instruction has been sacrificed in an effort by the hospital to pass the measure. We consider measuring of the quality of discharge instructions as a different measure that should be considered in the future. 2. Abstraction of the Discharge Instructions Address Medications data element is challenging. The process of compiling a final list of all medications being prescribed at discharge and then comparing this list to the list given to the patient, to confirm completeness, requires substantial time from the abstractors, given the nature of this documentation in the medical record (e.g., conflicting documentation amongst sources, loose references such as "continue same medications", medications referenced by class and not named such as "Sent home on beta-blocker", handling of vitamins, food supplements, etc. where documentation tends to be less specific, records without documentation necessary to build a comparison list, matching up of brand or trade names vs. generic names, therapeutic substitutions made by the pharmacy). A necessary complex set of data abstraction guidelines has evolved to assist the abstractor to determine just how to classify discharge medication matches/mismatches, given the many different ways medications can be referenced. Abstraction guidelines are reviewed and revised on an ongoing basis, in an effort to reduce burden. Additionally, fact sheets which summarize important abstraction principles are published to help abstractors with data collection. 3. The data elements used in this measure are closely tracked. Questions submitted by abstractors are recorded, and trends related to published abstraction guidelines and disagreements over measure inclusions and exclusions in general are discussed in-depth every 6 months. Revisions in measure specifications, including data element definitions, are made as issues surface (e.g., how to determine from documentation whether a copy of the instruction sheet was actually given to the patient, how to handle documentation of a plan to start a medication at discharge in terms of identifying discharge medications, what constitutes acceptable instructions for activity, diet, etc.). The frequency of questions pertaining to each data element are tracked by the Hospital Inpatient Quality Reporting Program QIOSC. Clearly the number of questions a data element receives is another indication of how difficult the specifications for the measure might be. Frequency reports are reviewed regularly, to help identify where issues in data element definitions may exist. Of note, in an August 2010 report run by the Hospital Inpatient Quality Reporting Program QIOSC, the number of questions about the abstraction of the discharge instructions elements amounted to 172, 44.1% of the total 390 Quest questions received for HF for that month (medication instructions accounted for 142 of the 172 questions - not unexpectedly, given the inherent issues with this element as briefly discussed in	4d CO PO MO NO

Comment [KP]: 4b. The required data elements are available in electronic sources. If the required data are not in existing electronic sources, a credible, near-term path to electronic collection by most providers is specified and clinical data elements are specified for transition to the electronic health record.

Comment [KP]: 4c. Exclusions should not require additional data sources beyond what is required for scoring the measure (e.g., numerator and denominator) unless justified as supporting measure validity.

Comment [KP]: 4d. Susceptibility to inaccuracies, errors, or unintended consequences and the ability to audit the data items to detect such problems are identified.

#2 above). Lastly, CDAC validation reports (which compare hospital data to CDAC data) and internal CDAC abstractor accuracy reports are monitored, to ensure good quality data. In sum, issues which may surface in questions submitted by users and CDAC validation/accuracy reports will continue to be closely monitored to identify any additional problems, and revisions will be made if warranted.	
4e. Data Collection Strategy/Implementation	
4e.1 Describe what you have learned/modified as a result of testing and/or operational use of the measure regarding data collection, availability of data/missing data, timing/frequency of data collection, patient confidentiality, time/cost of data collection, other feasibility/ implementation issues: The decision points relating to exclusions comfort measures only, clinical trial, and discharge disposition in the algorithms were rearranged for April 2008+ discharges. The new order enabled tool developers to program tools in such a way that the abstractor could skip abstraction of Comfort Measures Only (challenging data to abstract from some medical records) if the patient was transferred to another acute care hospital, left AMA, expired, or was discharged to hospice, saving valuable abstraction time. Additionally, given the number of problems that were surfacing as abstractors attempted abstraction too soon after discharge, we now advise abstractors to hold off on data collection until the discharge summary is filed in and the chart is complete and closed whenever possible. Not only does this enable the abstractor to gather as much information about the hospitalization as possible (capture important information that may not have been present in the chart earlier), but if picked for validation, this will reduce the number of potential mismatches that can occur when the CDAC is abstracting from what amounts to a different chart than what the hospital abstractor used. 4e.2 Costs to implement the measure (costs of data collection, fees associated with proprietary measures): Varies according to data collection method (use of vendor) and type of abstractor used to collect clinical data. Many hospitals have implemented standardized medical record documentation processes to reduce abstraction burden related to this measure. 4e.3 Evidence for costs: N/A 4e.4 Business case documentation: N/A	4e C● P● M● N●
TAP/Workgroup: What are the strengths and weaknesses in relation to the subcriteria for Feasibility?	4
Steering Committee: Overall, to what extent was the criterion, Feasibility, met?	4
Rationale:	C● P● M● N●
RECOMMENDATION	
(for NQF staff use) Check if measure is untested and only eligible for time-limited endorsement.	Time-limited ●
Steering Committee: Do you recommend for endorsement?	Y●
Comments:	N● A●
CONTACT INFORMATION	
Co.1 Measure Steward (Intellectual Property Owner)	
Co.1 Organization	
Centers for Medicare & Medicaid Services, 7500 Security Boulevard , Baltimore, Maryland, 21244-1850	
Co.2 Point of Contact	

Comment [KP]: 4e. Demonstration that the data collection strategy (e.g., source, timing, frequency, sampling, patient confidentiality, etc.) can be implemented (e.g., already in operational use, or testing demonstrates that it is ready to put into operational use).

Edward Q., Garcia III, MHS, Health Policy Analyst, MMSNQF@hsag.com, 410-786-6738-
Measure Developer If different from Measure Steward Co.3 Organization Centers for Medicare & Medicaid Services, 7500 Security Boulevard, Baltimore, Maryland, 21244 Co.4 Point of Contact Kristie, Baus, Kristie.Baus@cms.hhs.gov, 410-786-6738-
Co.5 Submitter If different from Measure Steward POC Wanda, Johnson, wjohnson@okqio.sdps.org, 410-786-6738-, Centers for Medicare & Medicaid Services
Co.6 Additional organizations that sponsored/participated in measure development The Joint Commission
ADDITIONAL INFORMATION
Workgroup/Expert Panel involved in measure development Ad.1 Provide a list of sponsoring organizations and workgroup/panel members' names and organizations. Describe the members' role in measure development. This measure is reviewed and maintained by the Heart Care Technical Expert Panel. Quarterly teleconferences are held to discuss issues pertinent to this measure (and its specifications) and potential revisions. Current members: Frederick Masoudi, MD, MSPH Workgroup Chair: Denver Health Medical Center, University of Colorado at Denver and Health Sciences Center Don Casey, MD, MPH, MBA: VP Quality and Chief Medical Officer, Atlantic Health, Rep. of the American College of Physicians Elizabeth Delong, PhD: Professor and Chair, Duke University, Biostatistics and Bioinformatics, Co-Director, Outcomes Research and Assessment Joseph Drozda, MD: Clinical Investigator, Mercy Health Research, Executive Committee Member, PCPI, Rep. of American Medical Association John P. Erwin, III: Professor of Medicine, Co-Director, Cardiovascular Fellowship Program, Hospital Champion, Acute Myocardial Infarction Quality Improvement, Scott and White Hospital and Clinic Kerri Fei: Senior Policy Analyst, Measure Development Operations, American Medical Association Susan Fitzgerald, RN, MS: Associate Director, Science and Quality, American College of Cardiology Gary Francis, MD: Professor of Medicine, University of Minnesota, Rep. of Heart Failure Society of America David C. Goff, MD, PhD: Professor and Chair, Department of Epidemiology and Prevention, Division of Public Health Sciences, Wake Forest University School of Medicine Kathleen Grady, CNS: Administrative Director, Center for Heart Failure, Bluhm Cardiovascular Institute Division of Cardiothoracic Surgery, Northwestern Memorial Hospital Darryl Gray, MD: Medical Officer, Agency for Healthcare Research and Quality Lee Green, MD: Professor, University of Michigan Medical School Ed Havranek, MD: Professor of Medicine, Denver Health Medical Center, University of Colorado School of Medicine Paul A. Heidenreich: Assistant Professor of Medicine, Associate Professor by courtesy of Health Research and Policy at the VA Palo Alto Health Care System and CHP/PCOR Fellow Alice C. Jacobs, MD: Professor of Medicine, Director, Cardiac Cath Lab, Boston University Medical Center Marvin Konstam, MD: Director, Cardiovascular Center, Tufts Medical Center, Rep. of Heart Failure Society of America Harlan Krumholz, MD: Harold H. Hines, Jr. Professor of Medicine and Epidemiology and Public Health, Yale University School of Medicine Jerod Loeb, PhD: Executive Vice President, Quality Measurement & Research, The Joint Commission Ann [Hiniker] Loth, RN, MS, CNS: Certified Clinical Nurse Specialist, Mayo Foundation Joseph Messer, MD, MACC: Professor of Medicine, Rush University Medical Center, Rep. of American Medical Association Eric Peterson, MD, MPH: Professor of Medicine, Director Cardiovascular Research, Duke Clinical Research Institute, Duke University Medical Center Martha Radford, MD: Chief Quality Officer, Professor of Medicine, New York University School of Medicine Rose Marie Robertson, MD: Chief Science Officer, American Heart Association John Rumsfeld, MD, PhD, FACC, FAHA: Staff Cardiologist, Cardiovascular Outcomes Researcher, Denver Veterans Affairs Medical Center

David Shahian, MD: Research Director, Center for Quality and Safety, Massachusetts General Hospital Melanie Shahriary, RN, BSN: Associate Director, Performance Measures and Data Standards, American College of Cardiology John Spertus, MD, MPH, FACC: Director of Cardiovascular Education and Outcomes Research, Mid America Heart Institute, University of Missouri Samantha Tierney: Senior Policy Analyst I, American Medical Association Gayle Whitman, PhD, RN, FAAN, FAHA: Sr Vice President, Office of Science Operations, American Heart Association Janet Wright, MD, FACC: Senior Vice President for Science and Quality, American College of Cardiology Contractor Staff: Dale Bratzler, DO, MPH: CEO, Principal Clinical Coordinator, Oklahoma Foundation for Medical Quality Jo DeBuhr, RN: Project Specialist, AMI/HF Inpatient Measures, Oklahoma Foundation for Medical Quality/Colorado Foundation for Medical Care Chris Leber, RN: Project Specialist, AMI/HF Inpatient Measures, Oklahoma Foundation for Medical Quality/Colorado Foundation for Medical Care CMS Staff: Kristie Baus, MS, RN: Government Task Leader, Centers for Medicare and Medicaid Services David Nilasena, MD: Chief Medical Officer, Region VI, Centers for Medicare and Medicaid
Ad.2 If adapted, provide name of original measure: N/A Ad.3-5 If adapted, provide original specifications URL or attachment
Measure Developer/Steward Updates and Ongoing Maintenance Ad.6 Year the measure was first released: 1999 Ad.7 Month and Year of most recent revision: 10, 2010 Ad.8 What is your frequency for review/update of this measure? Every 6 months Ad.9 When is the next scheduled review/update for this measure? 07, 2011
Ad.10 Copyright statement:
Ad.11 Disclaimers:
Ad.12 -14 Additional Information web page URL or attachment:
Date of Submission (MM/DD/YY): 12/14/2010